Research map: Transforming routine solid tumor profiling with automated next-generation sequencing: experience from a reference general hospital

Back to the article

Papers in this map

  1. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer · Patrick M. Forde · 2022 · 2741 citations · Cited by this paper
  2. Clinicopathological analysis of 21 cases of “Synchronous” endocervical and ovarian adenocarcinomas · 2026 · Related
  3. Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer · Heather A. Wakelee · 2023 · 1148 citations · Cited by this paper
  4. Combined inverted follicular keratosis and adnexal tumors: a series of 12 cases · 2026 · Related
  5. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up · Lizza E.L. Hendriks · 2023 · 859 citations · Cited by this paper
  6. Clinicopathological features and risk stratification for lymph node metastasis in early-stage colorectal cancer (from intramucosal carcinoma to SM2): a large-scale retrospective study based on a Chinese population · 2026 · Related
  7. Non–Small Cell Lung Cancer, Version 4.2024 · Gregory J. Riely · 2024 · 841 citations · Cited by this paper
  8. High performance deep-learning model for the diagnosis of auto-immune hepatitis based on histological whole slide images · 2026 · Related
  9. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) · Joaquı́n Mateo · 2018 · 833 citations · Cited by this paper
  10. ASPSCR1::TFE3-rearranged renal cell carcinomas: clinicopathologic, molecular, and survival analysis of 30 cases · 2026 · Related
  11. Glioma targeted therapy: insight into future of molecular approaches · Keyang Yang · 2022 · 741 citations · Cited by this paper
  12. MYD88L265P mutation is a highly specific marker for the nonGCB/ABC DLBCL molecular subtype · 2026 · Related
  13. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial · Roy S. Herbst · 2023 · 418 citations · Cited by this paper
  14. Immune-related pathologic response (irPR) features and immunotherapeutic response score (ITRS) predict survival following neoadjuvant/conversion combined immunotherapy in intrahepatic cholangiocarcinoma · 2026 · Related
  15. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group · Maria Fernanda Mosele · 2024 · 409 citations · Cited by this paper
  16. GPR143, a novel immunohistochemical marker for renal tumors with FLCN/TSC/MTOR-TFE alterations · 2026 · Related
  17. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions · Caicun Zhou · 2023 · 378 citations · Cited by this paper
  18. Sarcomatous transformation of an astrocytoma IDH-mutant following radiotherapy · 2026 · Related
  19. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research · C. Marchiò · 2019 · 372 citations · Cited by this paper
  20. Clinical Utility of Comprehensive Genomic Profiling for Advanced Non‐Small Cell Lung Cancer: A Single‐Center Retrospective Study · 2025 · Related
  21. Dabrafenib plus trametinib in patients with BRAFV600E-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial · Patrick Y Wen · 2021 · 370 citations · Cited by this paper
  22. NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022 · Craig Horbinski · 2023 · 240 citations · Cited by this paper
  23. Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma · Gajanan Kendre · 2022 · 176 citations · Cited by this paper
  24. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis · Kang Qin · 2020 · 165 citations · Cited by this paper
  25. Oncogenic alterations in advanced NSCLC: a molecular super-highway · Alex Friedlaender · 2024 · 135 citations · Cited by this paper
  26. Molecular Pathology of Gliomas · Kristyn Galbraith · 2021 · 85 citations · Cited by this paper
  27. The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy · Matteo Canale · 2022 · 84 citations · Cited by this paper
  28. Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC · Helei Hou · 2019 · 83 citations · Cited by this paper
  29. Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs · Matteo Canale · 2020 · 75 citations · Cited by this paper
  30. Treatment Strategies for KRAS-Mutated Non-Small-Cell Lung Cancer · E O'Sullivan · 2023 · 73 citations · Cited by this paper
  31. ESMO Scale for Clinical Actionability of Molecular Targets Driving Targeted Treatment in Patients with Cholangiocarcinoma · Helena Verdaguer · 2022 · 71 citations · Cited by this paper
  32. Navigating bottlenecks and trade-offs in genomic data analysis · Bonnie Berger · 2022 · 65 citations · Cited by this paper
  33. Molecular profiling in cholangiocarcinoma: A practical guide to next-generation sequencing · Albrecht Stenzinger · 2023 · 65 citations · Cited by this paper
  34. Prognostic Value of Epidermal Growth Factor Receptor Mutations in Resected Non-Small Cell Lung Cancer: A Systematic Review with Meta-Analysis · Zhixuan Zhang · 2014 · 64 citations · Cited by this paper
  35. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center’s experiences · Minho Cho · 2017 · 60 citations · Cited by this paper
  36. Priorities to accelerate workflow automation in health care · Teresa Zayas‐Cabán · 2022 · 59 citations · Cited by this paper
  37. Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology · Al B. Benson · 2025 · 54 citations · Cited by this paper
  38. Future perspective for the application of predictive biomarker testing in advanced stage non-small cell lung cancer · Vincent D. de Jager · 2024 · 53 citations · Cited by this paper
  39. Developments in predictive biomarker testing and targeted therapy in advanced stage non-small cell lung cancer and their application across European countries · Vincent D. de Jager · 2024 · 52 citations · Cited by this paper

Source: OpenAlex (CC0)